Summary
For Year 2026-27, Jenburkt Pharmaceuticals reports the following shareholding: Total Promoters at 46.65%, Mutual Fund at 0%, Insurance at 0%, Foreign Institutional Investors at 0%, Domestic Institutional Investors at 0.12%, and Retail at 53.24%. This breakdown provides a quick snapshot of ownership distribution for Jenburkt Pharmaceuticals in 2026-27.
Jenburkt Pharmaceuticals FAQs
As of 04-2026, the promoter shareholding in Jenburkt Pharmaceuticals stands at 46.65% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Jenburkt Pharmaceuticals is 0% and 0.12% respectively.
The retail shareholding of the Jenburkt Pharmaceuticals is 53.24%.
Changes in shareholding patterns of Jenburkt Pharmaceuticals can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Jenburkt Pharmaceuticals are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
Jenburkt Pharmaceuticals Associated Pages
- Jenburkt Pharmaceuticals Share Price
- Jenburkt Pharmaceuticals Share Price chart
- Jenburkt Pharmaceuticals Fundamental Analysis
- Jenburkt Pharmaceuticals Technical Analysis
- Jenburkt Pharmaceuticals Peer Comparison
- Jenburkt Pharmaceuticals Share Price History
- Jenburkt Pharmaceuticals Dividend
- Jenburkt Pharmaceuticals Board of Directors
